Ultragenyx Pharma (RARE) Announces Positive Interim Data from KRN23 Phase 2 in TIO
Tweet Send to a Friend
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) announced positive interim data from the Phase 2 study of KRN23 for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
